Leveraging the T-Charge Superscript Platform for Transformative Efficacy in Autoimmune Diseases
Time: 2:45 pm
day: Day 2 - Track C - PM
Details:
- YTB323, a rapid-manufactured CD19-CAR-T enhances in vivo CAR-T expansion while preserving T-cell stemness
- YTB323 has demonstrated favourable benefit-risk in lymphoma with potential for reduced vein-to-vein timelines
- Emerging clinical data from YTB323 in severe refractory SLE supports the use of T-charge superscript manufactured CD19-CAR-T in autoimmune diseases
